21 CFR 207.69
中国药品企业的 FDA 美国代理人
向美国出口产品的中国药品企业必须向 FDA 注册,并指定一名位于美国境内的美国代理人(21 CFR 207.69)。在 2025-10 to 2026-09 的 12 个月内,FDA 拒绝了来自中国的 2,749 个进口条目,并有 85 项 FDA 进口警示列有来自中国的企业。
中国的 FDA 数据
数据来自 FDA 公开数据,检索日期 2026-10-21。召回数量按召回企业所在国家统计。
进口拒绝,2025-10 to 2026-09
| 被拒绝的进口条目 | 2,749 |
| 涉及注册或列名问题的拒绝 | NOT LISTED-118 · 388 FRNMFGREG-3280 · 279 |
最常见的拒绝理由
| 代码 | 数量 |
|---|---|
| TP NO PMTA-3842 This article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act because it is a tobacco product that FDA has found to be adulterated under section 902(6)(A) of the FD&C … | 415 |
| MELAMINE-3421 The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to bear or contain a food additive, namely melamine and/or a melamine analog, that is unsafe within the… | 401 |
| TP NO SE-3843 This article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act because it is a tobacco product that FDA has found to be misbranded under section 903(a)(6) of the FD&C A… | 396 |
| NOT LISTED-118 The article is subject to refusal of admission pursuant to section 801(a)(3) of the FD&C Act in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on the information… | 388 |
| FRNMFGREG-3280 The article is subject to refusal of admission pursuant to section 801(a)(3) in that it appears to be misbranded as defined in section 502(o) of the FD&C Act. Based on information available to FDA, i… | 279 |
列有中国企业的进口警示
至少列有一家中国企业的进口警示:85 项。近期更新:
- Import Alert 16-129: Detention Without Physical Examination of Seafood Products Due to Nitrofurans
- Import Alert 16-39: Detention Without Physical Examination of Ready-to-Eat Seafood for Listeria monocytogenes
- Import Alert 45-02: Detention Without Physical Examination and Guidance of Foods Containing Illegal and/or Undeclared Colors.
- Import Alert 45-06: Detention without Physical Examination of Stevia Leaves, Crude Extracts of Stevia Leaves and foods Containing Stevia Leaves and/or Stevia Extracts
- Import Alert 99-05: Detention Without Physical Examination Of Raw Agricultural Products for Pesticides
- Import Alert 99-08: Detention without Physical Examination of Processed Human and Animal Foods for Pesticides
中国企业的召回,近 5 年
33 (Class II: 22, Class I: 11)
近期召回原因:
- 2026-04 This recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing fa…
- 2026-03 CGMP Deviations This recall has been initiated due to failing to complete process validation and bacterial endotoxin method validation before distribution
- 2025-10 cGMP Deviations
法规要求
生产、重新包装、重新贴标或回收处理进口或拟进口至美国的药品的外国企业,必须以电子方式向 FDA 注册、列出其药品,并指明一名居住在美国或在美国设有营业场所的美国代理人。注册每年在 10 月 1 日至 12 月 31 日之间更新。
- 成品人用药和兽用药的外国制造商,包括非处方(OTC)产品和洗手液
- 其产品进口至美国的外国原料药(API)制造商、重新包装商和重新贴标商
截止日期
- 在开始运营后 5 个日历日内注册(21 CFR 207.21)
- 每年 10 月 1 日至 12 月 31 日之间更新(21 CFR 207.29)
- 每年 6 月和 12 月更新药品列名,或声明无变更
步骤
- 为企业获取 DUNS 号码
- 如果将以自己的名义列出产品,请申请标签商代码
- 准备用于注册和列名的结构化产品标签(SPL)文件
- 通过 FDA 的电子提交网关或 CDER Direct 提交
- 美国代理人在注册中列明,FDA 会联系其进行确认
常见错误
- 提交的 SPL 所用 DUNS 的地址不一致
- 错过年终的列名确认
- 认为注册或 NDC 号码就意味着 FDA 已批准该药品。事实并非如此
US Agent Desk 如何提供帮助
我们担任您的美国代理人,用您的语言准备注册资料供贵公司的负责人提交,在 FDA 要求时确认指定,并每天早晨查看 FDA 公开记录中与贵公司有关的内容。价格从每年 $990 起。
来源
独立的私营服务。与美国 FDA 无隶属关系。不构成法律意见。